The use of inhibitors in studies on protein synthesis.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000963:Antimetabolites / Q000494:pharmacology*; D002701:Chloramphenicol / Q000494:pharmacology; D005672:Fusidic Acid / Q000494:pharmacology; D007612:Kanamycin / Q000494:pharmacology; D007700:Kinetics; D008722:Methods; D008954:Models, Biological; D009355:Neomycin / Q000494:pharmacology; D010441:Peptide Chain Elongation, Translational / Q000187:drug effects; D010442:Peptide Chain Initiation, Translational / Q000187:drug effects; D010443:Peptide Chain Termination, Translational / Q000187:drug effects; D010445:Peptide Elongation Factors; D010448:Peptide Initiation Factors; D010454:Peptide Termination Factors; D014176:Protein Biosynthesis / Q000187:drug effects*; D011691:Puromycin / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D012270:Ribosomes / Q000187:drug effects / Q000378:metabolism; D013307:Streptomycin / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology; D014233:Tricarboxylic Acids / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000963:Antimetabolites; D010445:Peptide Elongation Factors; D010448:Peptide Initiation Factors; D010454:Peptide Termination Factors; D012333:RNA, Messenger; D014233:Tricarboxylic Acids; D011691:Puromycin; D007612:Kanamycin; D005672:Fusidic Acid; D002701:Chloramphenicol; D013752:Tetracycline; D009355:Neomycin; D013307:Streptomycin